Get Premium Data for Cyber Monday: Up to 55% Off InvestingProCLAIM SALE

Abbott Laboratories (ABT)

NYSE
Currency in USD
115.59
-0.38(-0.33%)
Closed
After Hours
115.72+0.13(+0.11%)
ABT Scorecard
Full Analysis
Has raised its dividend for 11 consecutive years
Fair Value
Day's Range
114.89116.29
52 wk Range
99.71121.64
Key Statistics
Edit
Prev. Close
115.97
Open
115.26
Day's Range
114.89-116.29
52 wk Range
99.71-121.64
Volume
3.27M
Average Volume (3m)
5.05M
1-Year Change
10.15%
Book Value / Share
unlockUnlock
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ABT Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
129.87
Upside
+12.35%
Members' Sentiments
Bearish
Bullish
ProTips
9 analysts have revised their earnings upwards for the upcoming period
Show more

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

Abbott Laboratories SWOT Analysis


Resilient Performance
Abbott Laboratories demonstrates strong financial results despite ongoing litigation challenges, maintaining its organic revenue growth outlook and increasing EPS guidance
Portfolio Strength
Explore Abbott's diverse product range across medical devices, diagnostics, nutrition, and pharmaceuticals, driving growth and mitigating risks in individual segments
Litigation Hurdles
Delve into the ongoing NEC litigation's impact on Abbott's stock performance and the potential timeline for resolution extending beyond 2025
Future Catalysts
Learn about Abbott's growth drivers, including emerging market expansion and innovation in diabetes care, with analyst price targets ranging from $125 to $149
Read full SWOT analysis
ABT Full Pro Research
Institutional-Grade Stock Analysis
Understand how ABT earns money
Financial health at a glance
Bearish and bullish outlooks
Latest expert insights
Actionable Pro Tips, and many more...
Gain access to 1400+ in-depth research reports on the most popular US stocks

Abbott Laboratories Earnings Call Summary for Q4/2024

  • Abbott reports 8% organic sales growth, raises guidance for third time in 2023; adjusted EPS at $1.21
  • Diabetes Care sales up 21% to $1.6B; new $7B share repurchase program authorized
  • Q4 adjusted EPS forecast $1.31-$1.37; high single-digit revenue growth, 10% EPS growth expected for 2025
  • Challenges in international pediatric nutrition; Core Lab Diagnostics impacted by China's regulatory changes
  • New products to generate ~$1B revenue this year; focus on expanding margins and disciplined investment
Last Updated: 2024/10/16, 21:52
Read Full Transcript

Compare ABT to Peers and Sector

Metrics to compare
ABT
Peers
Sector
Relationship
P/E Ratio
34.9x−8.8x−0.7x
PEG Ratio
2.91−0.240.00
Price/Book
5.0x4.5x2.6x
Price / LTM Sales
4.9x4.0x3.2x
Upside (Analyst Target)
12.1%31.8%44.1%
Fair Value Upside
Unlock−12.3%8.2%Unlock

Analysts' Recommendations

21 Buy
5 Hold
1 Sell
Ratings:
24 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 129.87

(+12.36% Upside)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 3.3
Dividend Yield
1.90%
Industry Median 0.73%
Annualised payout
2.2000
Paid quarterly
5-Years Growth
+11.44%
Growth Streak

FAQ

What Is the Abbott Labs (ABT) Stock Price Today?

The Abbott Labs stock price today is 115.59

What Stock Exchange Does Abbott Labs Trade On?

Abbott Labs is listed and trades on the NYSE stock exchange.

What Is the Stock Symbol for Abbott Labs?

The stock symbol for Abbott Labs is "ABT."

Does Abbott Labs Pay Dividends? What’s The Current Dividend Yield?

The Abbott Labs dividend yield is 1.90%.

What Is the Abbott Labs Market Cap?

As of today, Abbott Labs market cap is 200.45B.

What is Abbott Labs Earnings Per Share?

The Abbott Labs EPS is 3.30.

What Is the Next Abbott Labs Earnings Date?

Abbott Labs will release its next earnings report on 21 Jan 2025.

From a Technical Analysis Perspective, Is ABT a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.